A prospective re-audit on insulin prescribing and administration practices in a university teaching hospital
Authors: Hogan-Murphy D , Cunningham D , Ero A , Uwadoka O , Given J , Cunningham A , Dennedy M C , Egan L , Hanrahan A , Ridhwann S 
Published: April 2024

Introduction

Insulin is a high-alert medication which can cause significant patient harm if used inappropriately and has been identified as a significant medication safety concern in Galway University Hospitals. The first hospital-wide insulin review[1] was conducted in 2022 to evaluate insulin prescribing/administration practices and identify/develop quality improvements inclusive of:

-The appointment of a senior pharmacist with a special interest in diabetes (June 2022),

-An updated insulin record (November 2022; previous edition June 2019),

-Development/implementation of a bespoke local eLearning module for the safe use of high-alert medications including insulin (March 2023), and

-Continuous education on appropriate use for healthcare staff and patients/carers.

Aim

The aim was to conduct a similar insulin study to assess performance since the previous review, and develop further quality improvements as needed.

Methods

This study was conducted over one day in June 2023 on 24 wards by 26 interprofessional data collectors. Inclusion criteria comprised inpatients prescribed and/or administered insulin for the previous 72 hours. Exclusion criteria comprised non-admitted patients, short stay wards, critical care, maternity, and psychiatry. The protocol and tool were approved by the local Clinical Audit Committee, piloted with four inpatients, and communicated to all data collectors prior to commencement. Generated data were anonymous and securely stored. Data analysis was carried out using Excel by three independent researchers to confirm reliability of results.

Results

In total 557 inpatients were reviewed, of which 21% (116/557) had diabetes and 10% (56/557) were prescribed insulin. Nearly three-quarters (73%; 41/56) were prescribed a meal-time supplement, whilst 68% (38/56) were prescribed regular insulin – of which 63% (24/38) comprised prescribing errors, an improvement from 78% (32/41) in 2022. Administration errors comprised 84% (32/38) of records, similar to the 88% (36/41) error rate observed in 2022. Approximately one-fifth (21%; 8/38) of insulin orders were not signed by a prescriber, compared to 12% (5/41) the previous year. More than nine out of ten prescribers clearly documented the correct insulin name, dose, and administration times, and 71% (27/38) documented a medical council registration number, bleep, or name for contact purposes, compared to 59% (24/41) the previous year. Failure to document administration times was noted in 42% (16/38) of instances compared to 46% (19; n=41) the previous year. Insulin was not double-checked by a second independent individual in 21% (8/38) of cases, compared to 29% (12; n=41) in 2022.

Conclusion

Results have identified an overall practice improvement. Building on recent interventions implemented and incorporating newer strategies will aid in enhanced insulin use. An updated version of the insulin record has been implemented due to the recent discontinuation of the referenced perioperative fluid and the introduction of non-referenced blood ketone monitors. High leverage strategies such as ePrescribing is a current consideration to standardise practices. Conducting a study over a longer period may identify further trends. Strengths include study robustness, interprofessional collaboration, and transferability to other hospitals. Disseminating results and promoting benefits should encourage Irish hospitals to participate in a standardised national annual review to optimise patient care.

References

1. Hogan-Murphy D, Cunningham D, Ero A et al. Insulin Prescribing, Administration, and Glucose Monitoring Trends in a Hospital Setting. Ir Med J 2022; 115:674-83